Obesity-Associated Hypertension
Recent Progress in Deciphering the Pathogenesis
Kamal Rahmouni

The worldwide epidemic of excess body weight, including overweight and obesity, is associated with increased prevalence of cardiovascular risks comprising hypertension—a condition that promotes stroke, heart disease, and end-stage organ damage, which are major causes of death and disability. The close relationship between excess adipose mass and hypertension is well documented, with population-based studies showing excess adiposity as the strongest known risk factor for hypertension in male and female subjects of different ages and races. In particular, patients with visceral or abdominal obesity are at the greatest risk of developing hypertension and other cardiovascular risks. Moreover, obesity is a major risk factor for resistant hypertension (ie, patients who have uncontrolled blood pressure, despite being on ≥3 antihypertensive medications).

Clinical and animal studies have documented that weight gain can raise arterial pressure, whereas weight loss has a beneficial effect on blood pressure control. However, there are many factors that influence the blood pressure response to weight change, leading to substantial interindividual variations. In this regard, accumulating evidence suggests that genetic variants may affect the sensitivity to weight loss, as well as blood pressure response to weight change. This is based on the observation that patients carrying certain polymorphisms related to obesity and hypertension seem more likely to benefit from dietary interventions for weight loss and blood pressure control.

Lifestyle modifications that promote weight loss are generally recommended as the first line of treatment for the increasing problem of obesity-associated hypertension. At first glance, this recommendation seems compelling, but evidence suggests that weight loss through lifestyle modifications for obesity-associated hypertension is neither simple nor sustained and is also not consistently effective as antihypertensive therapy. Given that excessive sympathetic activity is common in obesity, β-blockers appear as an obvious pharmacological therapy to treat the hypertension associated with this condition, but treatment with β-blockers leads to metabolic complications including weight gain. Thus, novel approaches are needed for better management of obesity-associated hypertension. However, designing better therapies will require enhancing our understanding of the pathophysiological processes and molecular pathways that account for the blood pressure elevation in obesity. Here, I will review the recent progress in deciphering the mechanisms linking obesity and hypertension.

Excessive Sympathetic Nerve Activity
Activation of the sympathetic nervous system, which is a common feature of obesity, is widely recognized as a major contributor to the development and maintenance of hypertension. Interestingly, sympathetic overdrive was also found to be closely related to subclinical cardiovascular and renal alterations that develop in obese subjects even in the absence of hypertension. The recent development of radiotelemetric measurement of sympathetic nerve traffic allowed a close assessment of the temporal relationship between obesity, sympathetic overdrive, and hypertension. Rabbits instrumented for telemetric recording of renal sympathetic activity and hemodynamic measurements were found to develop a rapid increase in renal sympathetic tone, blood pressure and heart rate, and impairment in baroreflex function when fed a high-fat diet. These changes appeared as soon a 1 week after starting the high-fat diet and sustained after 3 weeks. Rats fed high-fat diet also exhibited a rapid increase in radiotelemetric lumbar sympathetic activity, which progresses with time, in parallel with hemodynamic and metabolic changes. Additional analysis revealed that high-fat feeding in rats increased lumbar sympathetic discharge during the entire 24-hour period, and this increase was primarily caused by a rise in burst amplitude and not through changes in burst frequency, indicating an increasing number of recruited nerve fibers.

Additional evidence demonstrating the critical role of the sympathetic nerves subserving the kidneys derives from studies using renal denervation in animal models of obesity, as well as obese patients. Selective ablation of the renal nerves abolished the hypertension in obese dogs, independently from changes in body weight. Interestingly, renal denervation did not lower the elevated heart rate or the plasma norepinephrine levels in the obese dogs. The mechanisms by which renal denervation normalizes blood pressure in obesity are not well understood. It also remains to be determined whether
disruption of sympathetic vasomotor pathways to beds other than the kidneys has beneficial effects on blood pressure and other cardiovascular alterations in obesity.

As a result of the significant technological advances achieved in recent years, novel devices targeting the sympathetic nervous system have been developed. An implantable device for bilateral electric baroreceptor stimulation that decreases sympathetic tone alleviates obesity-associated hypertension in experimental and clinical settings.23–24 Another interventional strategy developed recently consists in the ablation of the renal sympathetic nerves with a radiofrequency-emitting catheter inserted percutaneously into the femoral artery in patients. Several open-label trials have documented the efficacy of renal denervation in subjects with resistant hypertension, many of whom are obese.25–28 This new strategy offered patients with resistant hypertension another therapeutic option that is relatively safe because it can be performed under local anesthesia. However, it should be noted that there are some inconsistencies in the efficacy of this approach between studies.29 Moreover, in a recent blinded, sham-controlled clinical trial, after 6 months, the blood pressure-lowering effect of renal denervation was not significantly different from that observed in the sham group.30 There are many factors that could account for these inconsistencies in the efficacy of renal denervation including the effectiveness of the denervation and possible interindividual variation in the response. Nonetheless, the disappointing outcomes of the recent clinical trial represent a major setback and set a high bar for future development and use for blood pressure management in patients with resistant hypertension.

### Brain Mechanisms

A wealth of information about the neuronal mechanisms that contribute to obesity-associated hypertension and sympathetic overdrive have been gathered in recent years.31 In particular, the brain melanocortinergic system has emerged as a crucial molecular pathway in the development of hypertension and other cardiovascular disorders in human obesity. The central melanocortin system consists of small peptides, derived from proopiomelanocortin (POMC) that is produced by a subset of neurons located mainly in the hypothalamus and brain stem. These peptides act on the melanocortin receptors, chiefly melanocortin receptor 4 (MC4R) and MC3R, distributed throughout the central nervous system. The melanocortin system has a powerful influence on energy homeostasis and is critically involved in mediating the metabolic, sympathetic, and cardiovascular effects of leptin and insulin.32–35

Patients carrying loss-of-function mutations in MC4R were found to be protected from obesity-associated elevation in blood pressure, heart rate, and sympathetic tone.36,37 Conversely, stimulation of the MC4R led to significant and dose-dependent increase in blood pressure in healthy overweight or obese subjects.38 These adverse cardiovascular effects of MC4R agonists detract from targeting this receptor for therapeutic use in the management of common human obesity, despite its potent weight-reducing action. These findings also highlight the importance of assessing the cardiovascular effects when drugs are being considered for obesity management.

Animal studies have also provided several pieces of evidence implicating the melanocortin system as a key player in obesity-associated hypertension. Genetic studies have shown that interference with several signaling pathways in POMC neurons prevents the elevation of arterial pressure in obesity. For instance, blocking the proinflammatory pathway in POMC neurons by ablation of the gene encoding the activator IκB kinase-β prevented the development of hypertension caused by high-fat diet in mice.38 Similarly, mice lacking leptin signaling in POMC neurons or in the arcuate nucleus of the hypothalamus, where most POMC neurons reside, through deletion of the leptin receptor itself39,40 or components of its signaling pathway such as the signal transducer and activator of transcription-341 are protected against obesity-associated hypertension. Together, these findings demonstrate that POMC neurons are critically involved in the development and maintenance of obesity hypertension.

Disruption of leptin receptor signaling in POMC neurons abolished the ability of exogenous leptin administration to increase blood pressure,39,41 which provides additional support to the notion that leptin is a critical hormone in coupling hypertension and obesity (Figure). In addition, these findings are consistent with the inability of leptin to increase renal sympathetic nerve traffic in mice bearing arcuate nucleus-specific deletion of the leptin receptor.42 Leptin receptor signaling in the subfornical organ has also been involved in mediating renal sympathetic nerve activity in a selective manner.43 Mice lacking the leptin receptor in the subfornical organ exhibited a blunted leptin-induced renal sympathetic excitation. However, these mice had unaltered body weight, food intake, and brown adipose tissue sympathetic responses to leptin.44 The fact that several brain nuclei are implicated in the renal sympathetic nerve activation triggered by leptin is consistent with the idea that leptin action in the brain involves a distributed network. The ability of leptin to signal through various brain sites may also explain how this hormone can differentially alter baroreflex control of regional autonomic efferents.45 This was also touted as a potential mechanism underlying selective leptin resistance in obesity.46

In a recent study, Machleidt et al.47 used microneurography to demonstrate that leptin causes sympathetic excitation in humans. They found that in young healthy men intravenous bolus administration of leptin caused a gradual increase in muscle sympathetic nerve activity that persisted for >2 hours. These data combined with previous findings48 suggest that leptin may be a major driver of cardiovascular sympathetic activation in human obesity just like in experimental obesity. It is worth noting that emerging evidences have extended the role of leptin and selective leptin resistance to other pathophysiological settings such as the fetal programming of obesity, hypertension, and sympathetic overdrive.47–49

The effectiveness of central administration of a leptin receptor antagonist in normalizing arterial pressure and renal sympathetic activity in obese rabbits provides direct evidence on the importance of leptin in driving hypertension and sympathetic overactivity in obesity.50 Notably, central administration of an insulin receptor antagonist to obese rabbits also
decreased arterial pressure but with no concomitant change in renal sympathetic traffic. This indicates that brain action of insulin is also involved in coupling obesity and hypertension (Figure). This seems to occur through sympathetic vasomotor pathways subserving beds other than the kidneys. Such possibility is consistent with the preserved ability of central action of insulin to increase lumbar, but not renal, sympathetic nerve traffic in obese mice. Strikingly, in obesity, both phosphatidylinositol 3-kinase signaling and MC4R are required for the sympathetic control by leptin and insulin (Figure). The phosphatidylinositol 3-kinase–MC4R axis mediates the preserved renal and lumbar sympathoexcitatory effects of leptin and insulin, respectively. In future studies, it will be important to determine the molecular and cellular mechanisms that underlie the uncoupling of the metabolic and cardiovascular actions of both leptin and insulin in obesity.

Contribution of Adipose Tissue

Adipose tissue is now recognized as a major player in the regulation of physiological functions including cardiovascular regulation. Adipose tissue influences physiological and pathophysiological processes through various mechanisms including its ability to produce and release factors that act in a paracrine fashion to alter vascular reactivity with pathophysiological implications in obesity. For instance, adipocyte-derived aldosterone has emerged as a new paradigm in linking obesity with vascular disease. Adipocytes were found to possess the components necessary for aldosterone synthesis. Moreover, this study revealed that adipocyte-derived aldosterone regulates vascular function in a paracrine manner. Finally, the increased aldosterone production by adipocytes in obesity was shown to contribute to the vascular changes associated with this condition. These findings indicate that adipose tissue may be the source of the elevated circulating aldosterone levels that is commonly found in obese patients. These observations are also consistent with the beneficial effects of mineralocorticoid receptor blockade on blood pressure in obese subjects even in those displaying resistant hypertension.

Perivascular adipose tissue was known to influence vascular reactivity by releasing a transferable relaxing factor that produces relaxation by activating potassium channels in vascular smooth muscle cells in visceral arteries. The anticontractile effects of perivascular adipose tissue have now been extended to peripheral skeletal muscle arteries and shown to involve the opening of a particular K+ channel (KCNQ) in smooth muscle. Moreover, targeting these K+ channels was found effective in reversing the decline in periventricular regulation of arterial tone and peripheral resistance in hypertensive rats.

Adipose tissue produces hormones that act in an endocrine manner including leptin, discussed above, and peptides such as angiotensinogen, the only known precursor of angiotensin II—the main effector of the renin–angiotensin system (RAS). The contribution of adipocyte-derived angiotensinogen to the circulating pool of this protein is well established, but its role in metabolic and blood pressure regulation was not clear. Yiannikouris et al have now directly assessed the relevance of the adipose tissue angiotensinogen to the development of obesity-associated hypertension by studying mice that lacks the angiotensinogen gene only in adipose tissue. Selective ablation of adipose tissue angiotensinogen did not alter the weight gain and other metabolic changes caused by high-fat diet, but it protected mice from hypertension. Perhaps the most intriguing observation in this study relates to the demonstration that adipose tissue modulates blood pressure through its profound effect on angiotensin II synthesis, but the mechanisms involved remain to be defined.

The significant effect of adipocyte-derived angiotensinogen on blood pressure has triggered great interest in understanding the genetic determinants of its regulation. Analysis of human adipose tissues obtained during surgery revealed a great variability in the total level of angiotensinogen gene expression among subjects. This analysis also showed enhanced levels
in the subcutaneous adipose tissue of the mRNA derived from a particular allele of the angiotensigen gene bearing the −20C variant in its promoter. This was associated with enriched binding to the −20C allele of a transcription factor, the upstream stimulatory factor 2, which is essential for angiotensigen transcriptional regulation. Additional studies are needed to examine the relevance of these genetic determinants in angiotensigen gene to obesity and hypertension.

In addition to its paracrine and endocrine influence on cardiovascular regulation, a recent study implicated afferent reflex originating from white adipose tissue in the control of blood pressure and sympathetic nerve activity and in linking obesity to hypertension and sympathetic activation. Capsaicin-mediated stimulation of afferent reflex originating from inguinal fat depot was found to increase efferent renal sympathetic discharge and blood pressure in rats. Notably, these sympathetic and pressor responses elicited by adipose afferent reflex activation were enhanced in obese animals. Conversely, disruption of the white adipose tissue sensory afferents caused a rapid and long-lasting decrease in renal sympathetic tone and arterial pressure in obese rats but not in controls. Moreover, obese rats given a leptin receptor antagonist into the inguinal and retroperitoneal fat depots exhibited a rapid decrease in renal sympathetic activity and arterial pressure that lasted for ≈15 minutes. These intriguing results indicate that leptin-mediated enhancement in white adipose tissue sensory afferent activity is a major pathophysiological mechanism of hypertension and vasomotor sympathetic overdrive in obesity.

**Renal Mechanisms**

Volume expansion and sodium retention are major features of obesity. The importance of altered renal excretory capacity in the pathogenesis of experimental and human hypertension is well established. Longitudinal studies have shown that alterations in renal excretory function occur before the onset of obesity hypertension in animal models and humans, indicating that renal dysfunction may drive arterial pressure elevation in obesity. The sodium retention associated with experimental obesity seems because of an increase in tubular reabsorption of sodium as indicated by the increased glomerular filtration rate and decreased fractional sodium excretion.

Obesity is associated with several other changes in the kidney that promote the development of hypertension, as well as chronic kidney disease and end-stage renal disease. These changes include fat accumulation, histological lesions, matrix expansion, inflammation, oxidant stress, fibrosis, and the presence of proteins in the urine. Interestingly, sex seems to influence the development of renal changes in obesity. This is based on the observation that female sheep are protected from adverse renal effects caused by obesity, despite exhibiting similar metabolic and cardiovascular phenotypes as the male counterparts.

Excessive sympathetic activity is a major cause of the abnormal sodium retention in obesity. This is supported by the finding that systemic sympathetic inhibition eliminated the renal abnormalities in obese dogs. However, despite its efficacy to control blood pressure, selective ablation of the renal nerves failed to correct the glomerular hyperfiltration observed in obesity. In fact, renal denervation in obese dogs led to an additional increase in glomerular filtration rate, whereas fractional sodium excretion remained suppressed. Thus, the mechanisms by which renal denervation correct obesity-associated hypertension remain unclear. It should be noted, however, that ablating the renal nerves in obesity reduced plasma renin activity presumably through inhibition of renin renin production and release. This finding points to the RAS as a potential mechanism by which renal denervation improves blood pressure control in obesity.

Several other mechanisms have been implicated in the renal changes that occur in obesity. For instance, improving insulin sensitivity in obese mice through protein tyrosine phosphatase 1B deletion corrected the reduced albumin excretion but not Na+ and K+ excretion nor the structural changes in the kidney. This finding points to a pathological role of insulin resistance in the albuminuria associated with obesity, although it is possible that such correction may reflect the normalization of arterial pressure. The type 2 scavenger receptor, CD36, and Na/K-ATPase have also emerged as key molecules in mediating the renal inflammation triggered by obesity in mice.

**Vascular Alterations**

Alterations in the vasculature including structural changes, endothelial dysfunction, enhanced contractile response, and altered stiffness are hallmarks of obesity. These vascular abnormalities are thought to contribute and even predict the development of hypertension and other cardiovascular complications. Consistent with the notion that in obesity vascular alterations precede hypertension, Weisbrod et al demonstrated that diet-induced obese mice develop arterial stiffness and endothelial dysfunction before the onset of hypertension. Importantly, obesity-associated vascular changes can be reversed by weight loss even after their establishment.

It should be noted, however, that vascular defects such as endothelial dysfunction are not universally associated with obesity. This is based on several studies showing the development of obesity without concomitant presence of vascular abnormalities. For instance, mice lacking the Bardet-Biedl syndrome 2 gene do not display endothelial dysfunction, despite the presence of obesity. More striking is the finding that salt-sensitive rats fed high-fat diet exhibit an improvement in endothelium-dependent vascular relaxation, despite the significant weight gain and the presence of several cardiovascular risks including elevated blood pressure and reduced renal function. The suppressed RAS seems to account for the improvement in endothelial function in obese salt-sensitive rats. The efficacy of chronic treatment with angiotensin 1−7, a peptide that negatively modulates RAS activity, in alleviating obesity-associated impairment in endothelium-dependent vasodilation supports further the pathophysiological role of the RAS in obesity-related endothelial dysfunction. Multiple other mechanisms, including sympathetic overdrive, inflammatory mediators, excessive reactive oxygen species production, and decreased nitric oxide bioactivity, may contribute to the deleterious effects of obesity on the vasculature.

**Conclusions and Perspectives**

The epidemic of obesity is associated with raising prevalence of cardiovascular risk factors including hypertension.
In parallel, this epidemic triggered a great interest in understanding the mechanisms underlying the adverse cardiovascular effects of obesity, which has led to significant progress in recent years. Defects in various biological processes ranging from genetic and humoral factors to basic cellular signaling pathways in different tissues have been involved in the pathogenesis of obesity-related hypertension. The diversity in the processes implicated is consistent with the polygenic and multifactorial nature of obesity and its comorbidities. The new knowledge gained in recent years should be taken into account when seeking novel diagnostic and therapeutic approaches for the cardiovascular disorders caused by excess adiposity. Given the evidence pointing to the significance of the neurogenic mechanisms in obesity-associated hypertension, new strategies that disrupt these processes should be favored. Despite the progress accomplished in recent years, there are many important issues that remain unaddressed. For instance, studies to dissociate the processes that are involved in the control of energy homeostasis versus blood pressure and vasoconstrictor sympathetic traffic should be pursued. This is necessary for the development of safe antiobesity drugs that do not compromise cardiovascular health. This will also allow the identification of strategies that can be used to treat hypertension without interfering with metabolic regulation. Also, despite the wide range of available antihypertensive drugs, there are still no specific guidelines for the treatment of hypertension in an obesity setting. Clinical trials are needed to address this issue. Finally, therapy for obesity-related hypertension should take into account progress in other research fields such as pharmacogenomics (ie, the genetic predisposition to drug response). Combining pharmacogenomics (and perhaps other omics such as proteomics) with patient characteristics and comorbidities will be useful to determine the most effective strategy to treat obesity-associated hypertension. This will allow hypertension care to move forward and enter the era of personalized medicine.

Sources of Funding
K. Rahmouni is supported by National Institutes of Health grant HL084207 and American Heart Association Established Investigator Award 14EIA18860041.

Disclosures
None.

References
220 Hypertension August 2014


Obesity-Associated Hypertension: Recent Progress in Deciphering the Pathogenesis
Kamal Rahmouni

Hypertension. 2014;64:215-221; originally published online May 12, 2014;
doi: 10.1161/HYPERTENSIONAHA.114.00920
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/64/2/215

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/